IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-47420-3.html
   My bibliography  Save this article

Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial

Author

Listed:
  • Zhongchao Li

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University)

  • Jing Liu

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University)

  • Bo Zhang

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University)

  • Jinbo Yue

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University)

  • Xuetao Shi

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University)

  • Kai Cui

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University)

  • Zhaogang Liu

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University)

  • Zhibin Chang

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University
    Shandong First Medical University and Shandong Academy of Medical Sciences)

  • Zhicheng Sun

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University
    Shandong First Medical University and Shandong Academy of Medical Sciences)

  • Mingming Li

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University
    Shandong First Medical University and Shandong Academy of Medical Sciences)

  • Yue Yang

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University
    Shandong First Medical University and Shandong Academy of Medical Sciences)

  • Zhao Ma

    (The Fourth People’s Hospital of Jinan)

  • Lei Li

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University)

  • Chengsheng Zhang

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University)

  • Pengfei Sun

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University)

  • Jingtao Zhong

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University)

  • Lei Zhao

    (Shandong Cancer Hospital Affiliated to Shandong First Medical University
    Shandong First Medical University and Shandong Academy of Medical Sciences
    The Affiliated Cancer Hospital of Xinjiang Medical University)

Abstract

Notable-HCC (NCT05185531) is a phase 1b trial, aiming to evaluate the safety and preliminary effectiveness of neoadjuvant PD-1 blockade plus stereotactic body radiotherapy (SBRT) in early-stage resectable hepatocellular carcinoma (HCC). Twenty patients with HCC of BCLC stage 0-A received 3 $$\times $$ × Gy SBRT and two cycles of tislelizumab, an anti-PD-1 monoclonal antibody before the curative HCC resection. Primary endpoints were the surgery delay, radiographic and pathological tumor response after the neoadjuvant therapy, safety and tolerability. During the neoadjuvant therapy, treatment-related adverse events (TRAEs) of grade 1-2 occurred in all 20 patients (100%), eight patients (40%) had grade 3 TRAEs, no grade 4 to 5 TRAE occurred, and all resolved without corticosteroids treatment. Per mRECIST, the objective response rate was 63.2% (12/19), with 3 complete response; the disease control rate was 100%. Two (10.5%) patients achieved complete pathological response. No surgery delay occurred. The neoadjuvant therapy did not increase the surgical difficulty or the incidence of complications. Secondary endpoints of disease-free survival and overall survival were not mature at the time of the analysis. Our pilot trial shows that neoadjuvant therapy with anti-PD-1 + SBRT is safe and promotes tumor responses in early-stage resectable HCC.

Suggested Citation

  • Zhongchao Li & Jing Liu & Bo Zhang & Jinbo Yue & Xuetao Shi & Kai Cui & Zhaogang Liu & Zhibin Chang & Zhicheng Sun & Mingming Li & Yue Yang & Zhao Ma & Lei Li & Chengsheng Zhang & Pengfei Sun & Jingta, 2024. "Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
  • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47420-3
    DOI: 10.1038/s41467-024-47420-3
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-47420-3
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-024-47420-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Mikhail Shugay & Dmitriy V Bagaev & Maria A Turchaninova & Dmitriy A Bolotin & Olga V Britanova & Ekaterina V Putintseva & Mikhail V Pogorelyy & Vadim I Nazarov & Ivan V Zvyagin & Vitalina I Kirgizova, 2015. "VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires," PLOS Computational Biology, Public Library of Science, vol. 11(11), pages 1-16, November.
    2. David A. Barbie & Pablo Tamayo & Jesse S. Boehm & So Young Kim & Susan E. Moody & Ian F. Dunn & Anna C. Schinzel & Peter Sandy & Etienne Meylan & Claudia Scholl & Stefan Fröhling & Edmond M. Chan & Ma, 2009. "Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1," Nature, Nature, vol. 462(7269), pages 108-112, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Qingnan Liang & Yuefan Huang & Shan He & Ken Chen, 2023. "Pathway centric analysis for single-cell RNA-seq and spatial transcriptomics data with GSDensity," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    2. Jani Huuhtanen & Dipabarna Bhattacharya & Tapio Lönnberg & Matti Kankainen & Cassandra Kerr & Jason Theodoropoulos & Hanna Rajala & Carmelo Gurnari & Tiina Kasanen & Till Braun & Antonella Teramo & Re, 2022. "Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    3. Emmanuel C. Patin & Pablo Nenclares & Charleen Chan Wah Hak & Magnus T. Dillon & Anton Patrikeev & Martin McLaughlin & Lorna Grove & Shane Foo & Heba Soliman & Joao P. Barata & Joanna Marsden & Holly , 2024. "Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    4. Wanzun Lin & Li Chen & Haojiong Zhang & Xianxin Qiu & Qingting Huang & Fangzhu Wan & Ziyu Le & Shikai Geng & Anlan Zhang & Sufang Qiu & Long Chen & Lin Kong & Jiade J. Lu, 2023. "Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    5. Kerry J. Laing & Werner J. D. Ouwendijk & Victoria L. Campbell & Christopher L. McClurkan & Shahin Mortazavi & Michael Elder Waters & Maxwell P. Krist & Richard Tu & Nhi Nguyen & Krithi Basu & Congron, 2022. "Selective retention of virus-specific tissue-resident T cells in healed skin after recovery from herpes zoster," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    6. Su Yin Lim & Elena Shklovskaya & Jenny H. Lee & Bernadette Pedersen & Ashleigh Stewart & Zizhen Ming & Mal Irvine & Brindha Shivalingam & Robyn P. M. Saw & Alexander M. Menzies & Matteo S. Carlino & R, 2023. "The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    7. Antonella Teramo & Andrea Binatti & Elena Ciabatti & Gianluca Schiavoni & Giulia Tarrini & Gregorio Barilà & Giulia Calabretto & Cristina Vicenzetto & Vanessa Rebecca Gasparini & Monica Facco & Iacopo, 2022. "Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    8. Michael D. Keller & Stefan A. Schattgen & Shanmuganathan Chandrakasan & E. Kaitlynn Allen & Mariah A. Jensen-Wachspress & Christopher A. Lazarski & Muna Qayed & Haili Lang & Patrick J. Hanley & Jay Ta, 2024. "Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication," Nature Communications, Nature, vol. 15(1), pages 1-9, December.
    9. Christel F. A. Ramirez & Daniel Taranto & Masami Ando-Kuri & Marnix H. P. Groot & Efi Tsouri & Zhijie Huang & Daniel Groot & Roelof J. C. Kluin & Daan J. Kloosterman & Joanne Verheij & Jing Xu & Seren, 2024. "Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinoma," Nature Communications, Nature, vol. 15(1), pages 1-24, December.
    10. Yuanyuan Qu & Xiaohui Wu & Aihetaimujiang Anwaier & Jinwen Feng & Wenhao Xu & Xiaoru Pei & Yu Zhu & Yang Liu & Lin Bai & Guojian Yang & Xi Tian & Jiaqi Su & Guo-Hai Shi & Da-Long Cao & Fujiang Xu & Yu, 2022. "Proteogenomic characterization of MiT family translocation renal cell carcinoma," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    11. Julia Joung & Paul C. Kirchgatterer & Ankita Singh & Jang H. Cho & Suchita P. Nety & Rebecca C. Larson & Rhiannon K. Macrae & Rebecca Deasy & Yuen-Yi Tseng & Marcela V. Maus & Feng Zhang, 2022. "CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    12. Kentaro Ohara & André Figueiredo Rendeiro & Bhavneet Bhinder & Kenneth Wha Eng & Hiranmayi Ravichandran & Duy Nguyen & David Pisapia & Aram Vosoughi & Evan Fernandez & Kyrillus S. Shohdy & Jyothi Mano, 2024. "The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    13. Yin Li & Manling Jiang & Ling Aye & Li Luo & Yong Zhang & Fengkai Xu & Yongqi Wei & Dan Peng & Xiang He & Jie Gu & Xiaofang Yu & Guoping Li & Di Ge & Chunlai Lu, 2024. "UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment," Nature Communications, Nature, vol. 15(1), pages 1-23, December.
    14. Min Wu & Tingting Wang & Nan Ji & Ting Lu & Ran Yuan & Lingxiang Wu & Junxia Zhang & Mengyuan Li & Penghui Cao & Jiarui Zhao & Guanzhang Li & Jianyu Li & Yu Li & Yujie Tang & Zhengliang Gao & Xiuxing , 2024. "Multi-omics and pharmacological characterization of patient-derived glioma cell lines," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    15. Xiaoping Su & Xiaofan Lu & Sehrish Khan Bazai & Linda Dainese & Arnauld Verschuur & Benoit Dumont & Roger Mouawad & Li Xu & Wenxuan Cheng & Fangrong Yan & Sabine Irtan & Véronique Lindner & Catherine , 2023. "Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumors," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    16. Roger Mulet-Lazaro & Stanley Herk & Margit Nuetzel & Aniko Sijs-Szabo & Noelia Díaz & Katherine Kelly & Claudia Erpelinck-Verschueren & Lucia Schwarzfischer-Pfeilschifter & Hanna Stanewsky & Ute Acker, 2024. "Epigenetic alterations affecting hematopoietic regulatory networks as drivers of mixed myeloid/lymphoid leukemia," Nature Communications, Nature, vol. 15(1), pages 1-22, December.
    17. Juan Blanco-Heredia & Carla Anjos Souza & Juan L. Trincado & Maria Gonzalez-Cao & Samuel Gonçalves-Ribeiro & Sara Ruiz Gil & Dmytro Pravdyvets & Samandhy Cedeño & Maurizio Callari & Antonio Marra & An, 2024. "Converging and evolving immuno-genomic routes toward immune escape in breast cancer," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    18. Chun-Hua Hung & Shang-Yin Wu & Cheng-I Daniel Yao & Hsuan-Heng Yeh & Chien-Chung Lin & Chang-Yao Chu & Tzu-Yu Huang & Meng-Ru Shen & Chun-Hung Lin & Wu-Chou Su, 2024. "Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer," Nature Communications, Nature, vol. 15(1), pages 1-24, December.
    19. Guillem Sanchez Sanchez & Stephan Emmrich & Maria Georga & Ariadni Papadaki & Sofia Kossida & Andrei Seluanov & Vera Gorbunova & David Vermijlen, 2024. "Invariant γδTCR natural killer-like effector T cells in the naked mole-rat," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    20. Prateek Kumar & Annie M. Goettemoeller & Claudia Espinosa-Garcia & Brendan R. Tobin & Ali Tfaily & Ruth S. Nelson & Aditya Natu & Eric B. Dammer & Juliet V. Santiago & Sneha Malepati & Lihong Cheng & , 2024. "Native-state proteomics of Parvalbumin interneurons identifies unique molecular signatures and vulnerabilities to early Alzheimer’s pathology," Nature Communications, Nature, vol. 15(1), pages 1-26, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47420-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.